Dutch biotech Crucell (CRCL.AS) said on Thursday it has resumed making its paediatric vaccines at a South Korean plant after it was forced to stop production last year because of contamination. Crucell, the target of a takeover by U.S. healthcare group Johnson & Johnson (JNJ.N), halted shipments from the facility in October because of microbiological contamination, sparking concerns that J&J might withdraw or lower its 1.75 billion euros bid for the company. "We have restarted production but...we are not shipping new product until we receive formal approval from the Korean FDA," Crucell spokeswoman Oya Yavuz said, confirming earlier comments from the World Health Organisation (WHO).
Source
